Regulatory effects of glucocorticoids (dexamethasone) on myeloma cells as well as bone resorption in multiple myeloma were investigated. Glucocorticoids significantly inhibited proliferation of myeloma cells, and decreased the messenger RNA (mRNA) expressions of interleukin-6 (IL-6) and secretory type immunoglobulin G (IgG). The inhibitory effects of glucocorticoids on myeloma cell proliferation could be due to the decreased expression of IL-6 mRNA. decreased IL-6 production, and thus suppression of autocrine growth by IL-6, which is an autocrine growth factor for myeloma cells as reported previously (Nature 332:83.
M der characterized by clonal proliferation of malignant plasma cells that secrete monoclonal immunoglobulin (M-protein), and also has a prominent feature of bone lytic lesions.' Recently, a regulatory mechanism of myeloma cell proliferation has been reported indicating interleukin-6 (IL-6) to be an autocrine growth factor for myeloma cells; ie, myeloma cells constitutively produce IL-6 and express IL-6 receptor,* and that IL-1 accelerates autocrine growth of myeloma cells through IL-6.' On the other hand, an osteolytic mechanism in myelomas has further been shown to be involved through an osteoclast activating factor (OAF) produced by the myeloma cells, although the OAF(s) produced by these myeloma cells is still controversial. Garrett et a14 reported that lymphotoxin was OAF from myeloma cells, but Kawano et al' found that IL-1 activities were detectable in the culture supernatants of freshly isolated myeloma cells, and that IL-lD rather than lymphotoxin exhibited the major bone resorbing activity in MMs.
In this report, to re-evaluate the effectiveness of glucocorticoids that have been used as chemotherapeutic agents in MM,6s7 we investigated the effects of glucocorticoids on the proliferation of myeloma cells, expression of secretory type Ig, mRNA, and bone resorption induced by IL-10 OAF. Our results showed that glucocorticoids not only have antiproliferative effects on myeloma cells, partly through the suppression of IL-6 production, but also have anti-osteolytic effects evidenced by inhibiting IL-1/3 production and simultaneously blocking osteoclast-activation by the secreted IL-18 and its subsequent effect on bone resorption. Thus, we propose that glucocorticoids could be more effective chemotherapeutic agents in multiple myeloma than we expected.
MATERIALS AND METHODS
Dexamethasone was purchased from Sigma (St Louis, MO). Recombinant human IL-lj3 and human IL-lj3 cDNA were kindly provided by Dr Y. Hirai (Otsuka Pharmaceutical Co, Ltd, Tokushima, Japan).' Human IL-6 cDNA was kindly provided by Drs T. Hirano and T. Kishimoto (Osaka University, Osaka, Japan)? Human immunoglobulin G (IgG) cDNA was a gift from Japanese Cancer Research Resources Bank (Tokyo, Japan). Calcitonin (Elcatonin) and synthetic human parathyroid hormone Reagents and cDNA. considered to be a major osteoclast activating factor (OAF) produced by myeloma cells, and glucocorticoids decreased the expression of IL-I@ mRNA and markedly suppressed the bone resorbing activity induced by IL-I@ OAF in 46Ca-release bone resorption assay, it is suggestive that glucocorticoids could inhibit bone resorption induced by IL-IB OAF in multiple myeloma. Therefore, from these data it is concluded that glucocorticoids could be more effective chemotherapeutic agents in multiple myeloma than we expected, especially with regards to the inhibitory effects on proliferation and M-protein secretion from myeloma cells, as well as bone resorption by myeloma cells. 0 1990 by The American Society of Hematology.
(PTH)-(1-34) (6,000 U/mg) were provided by Toyo Jozo Co (Tokyo, Japan).
Myeloma cells were highly purified from bone marrow aspirates in patients with IgG myelomas as described previously.'@'' Briefly, bone marrow cells were centrifuged on Ficoll-Hypaque gradient, followed by Percoll (Pharmacia, Uppsala, Sweden) discontinuous gradient ranging from 30% to 90% (vol/vol). Cells banding at the interface between 45% and 50% P e r d l were collected, and were subjected to E-rosetting. Non-Erosetting cells were treated with Leu M1 antibody (BectonDickinson, Sunnyvale, CA) and rabbit complement (Hoechst Behring, Marburg, West Germany). Thus, obtained purified myeloma cells consisted of more than 90% myeloma cells and were contaminated with fewer than 1% of either OKT3+ T cells, myeloid cells or erythroid cells. Myeloma cell-rich fractions, obtained as described above, were cultured at 4 x lo4 cells/mL in 0.2 mL of RPMI-I640 medium (Nissui, Tokyo, Japan) supplemented with 10% fetal calf serum (FCS; M.A. Bioproducts, Walkersville, MD)" and 1 x mol/L 2-mercaptoethanol (2-ME) in the presence of lo-', or mol/L dexamethasone for 48 hours in a humidified 5% CO, atmosphere at 37OC. Cells were pulsed with 1 pCi of 'H-thymidine (3H-TdR, 5
Ci/mmol, Amersham, Buckinghamshire, UK) 12 hours before harvesting, and DNA synthesis was measured by 'H-TdR uptake.
IgG, IL-6, and IL-Ij3 mRNA expression. Total RNA was
Myeloma cell purification.
In vitro proliferation activity of myeloma cells. isolated from myeloma cells after 24-hour culture in the presence of or IO-' mol/L dexamethasone by a guanidine isothiocyanate method with cesium chloride modification." RNA (10 pg) was subjected to electrophoresis through 1 % agarose gel containing 6% formaldehyde. After electrophoresis, RNA was transferred to NYTRAN filter (Schleicher & Schuell, Keene, NH). Filters were dried; baked at 8OoC for 2 hours in vacuo; prehybridized at 42OC for 24 hours in a prehybridization buffer containing 50% formamide, 5X SSC, 1X Denhardt's solution, 10% dextran sulfate, 50 mmol/L sodium phosphate buffer (pH 6.5), 1% SDS, 0.1 mg/mL denatured salmon sperm DNA, and 0.05 mg/mL tRNA: and then hybridized at 42OC for 48 hours in the same buffer containing a heat-denatured plasmid DNA encoding human IgG, IL-6, and IL-I@ radiolabeled with [(u-~*P]~CTP (3, 000 Ci/mmol, Amersham) by a random primer method. Filters were washed twice in 2X SSC at 1% SDS at 25OC for 30 minutes and twice in 0.2X SSC and 1% SDS at 6OoC for 30 minutes, and were exposed at -7OOC to Kodak XAR film (Eastman Kodak, Rochester, NY).
Bone resorbing activity was measured by a method described previo~sly.'~ In brief, 2-day-old mice (ddy-ATD) were injected with 1 pCi of (45Ca) CaCI, (Amersham). Two days later, the parietal bones were dissected and each bone was incubated in Eagle Minimal Essential Medium (Nissui, Tokyo, Japan) supplemented with 5% horse serum (GIBCO, Grand Island, NY). Twenty-four hours later, the medium was changed to a fresh one with or without the test substance. Culture was continued for the following 48 hours, and the bone pieces and the culture supernatants were removed. The radioactivities in the bone pieces and culture supernatants were measured in a @-scintillation counter (Tri-Carb 460 C, Packard, IL). Bone resorbing activity was expressed as the percentage of 4sCa released or as the ratio of the 45Ca released from the treated bones to the amount released from corresponding control bones. At least six bone pieces were used for each concentration of the tested substance. Statistical significance was evaluated by the Student's t test.
Bone resorption assay.

RESULTS
Efect of dexamethasone on in vitro proliferation of myeloma cells. Myeloma-rich fractions were cultured in the presence of various concentrations of dexamethasone mol/L) for 48 hours. As shown in Fig 1,  ' H-TdR uptakes of these myeloma cells was suppressed significantly in a dose-dependent manner. A similar phenomenon was found when myeloma cells were cultured for 24 of 72 hours (data not shown). It should be noted that the inhibitory effects of dexamethasone on myeloma cell proliferation depended on myeloma cells isolated from various cases of myelomas. Dexamethasone also suppressed IL-6-induced proliferation of myeloma cells in a dose-dependent manner. On the other hand, exogenous excessive amounts of IL-6 overcame the anti-proliferative effects of dexamethasone (data not shown). Calcitonin had no inhibitory effects on the proliferation of myeloma cells that we tested (data not shown). These results show that dexamethasone or glucocorticoids have an inhibitory effect on proliferation of myeloma cells.
Effect of dexamethasone on the expression of IL-6, IgG, and IL-1 ( 3 ity that dexamethasone inhibited production of IL-6 in these myeloma cells. To confirm this, we investigated whether dexamethasone decreased the expression of IL-6 mRNA. As shown in Fig 2A, dexamethasone markedly decreased the expression of IL-6 mRNA when the myeloma cells were cultured for 24 hours with 1 x mol/L dexamethasone. This was also the case when myeloma cells were cultured for 48 hours or with 1 x mol/L dexamethasone (data not shown).
Dexamethasone also suppressed the expression of secretory type IgG mRNA in myeloma cells (Fig 2B) . This could also be explained in this way: dexamethasone inhibited M-protein secretion of myeloma cell.
Furthermore, IL-1P rather than lymphotoxin is a major OAF in myelomas, as reported previ~usly,~ and IL-lP as well as IL-la also accelerate autocrine growth of myeloma cells through IL-6.3 Thus, we investigated the effect of dexamethasone on the expression of IL-10 mRNA in myeloma cells. The expression of IL-1P mRNA in myeloma cells was markedly suppressed when myeloma cells were cultured for 24 hours with 1 x mol/L dexamethasone as shown in Fig 2C . Similar results were also obtained when myeloma cells were cultured for 48 hours or with 1 x mol/L dexamethasone (data not shown). It is not likely that the suppressive effect of dexamethasone could have been derived from the cytotoxic effect on myeloma cells because viability of these myeloma cells, determined by trypan blue dye exclusion after 24-or 48-hour culture with dexamethasone (1 x or 1 x IO-' mol/L), was not significantly altered. In addition, I F N a suppressed the expression of IL-6 and IgG, but not IL-1P mRNA, as described previou~ly.'~ On the other hand, calcitonin had no significant effects on the expression of the mRNAs in these myeloma cells. These IL-1 8 mRNA data showed that dexamethasone significantly suppressed the expression of IL-6, IgG, and IL-lj3 mRNA in myeloma cells. Effect of dexamethasone on IL-lj3 (OAF)-induced bone resorption. Dexamethasone suppressed the expression of IL-1j3 mRNA in myeloma cells as shown above. Thus, we investigated the effect of dexamethasone on bone resorption induced by IL-lj3 (OAF). Dexamethasone inhibited bone resorption induced by culture supernatants of myeloma cells (case 1, IgG-x, stage IIIA, multiple bone lytic lesions; case 2, BJP-K, stage IIIB, multiple bone lytic lesions) as shown in Fig  3. Dexamethasone itself had no effect on spontaneous bone resorption. Bone resorbing activity in the culture supernatants has been shown to be derived mainly from IL-l@; ie, the bone resorbing activity was completely blocked by anti-ILlj3 antibody.' This is a confirmation of the finding that dexamethasone inhibited bone resorption induced by the recombinant IL-lj3.
On the other hand, parathyroid hormone (PTH) had a strong bone resorbing activity, and dexamethasone significantly augmented the effect of PTH on bone resorption. On the contrary, calcitonin markedly suppressed bone resorption induced by culture supernatants from myeloma cells.
Therefore, these results show that dexamethasone inhibits bone resorption induced by IL-lj3 (OAF) as well as IL-lj3 production in the myeloma cells. 
DISCUSSION
The main finding reported here is that glucocorticoids (dexamethasone) inhibited proliferation and M-protein secretion of myeloma cells by suppressing IL-6 mRNA expression and decreasing the levels of secretory type Ig mRNA, respectively. It also inhibited IL-1j3 production in myeloma cells as well as bone resorption induced by IL-lj3 OAF. These were also confirmed that IL-I activity (mouse thymocyte comitogenic assay),I6 IL-6 activity (IL-64ependent mouse hybridoma MH60, BSF2 proliferation assay),2 and IgG level (enzyme-linked immunosorbent assay)" were decreased in the culture supernatants of dexamethasone-treated myeloma cells (data not shown). In these experiments, the suppressive dose (lo-' to mol/L) of dexamethasone was in the pharmacologic range.
Glucocorticoids have been reported to modulate mRNA expression of eukaryotic genes; glucocorticoids increased the mRNA expression of mammary tumor virus," growth hormone in rat pituitary cells,18 metallothioneins in mouse liver," tyrosine aminotransferase in rat liver,2' a 2 p globulin in transfected mouse cells,2' and ovalbumin in chick oviduct22; whereas they decreased the mRNA expression of c-myc, c-myb, and c-Ki-ras in mouse lymphoid ~e l l s , 2~ adrenocorticotropin in rat pituitary glands,24 a-fetoprotein in developing rat liver?' tumor necrosis factor in macrophages,26 IL- The genes of IL-la and IL-lj3 have parts of consensus G R E sequences at intron 6 and intron 5 , respectively.33334 The IL-6 gene has G R E sequences in the 5'-flanking r e g i~n .~' Therefore, it is relevant to expect that glucocorticoids inhibit the gene expression of IL-1 and IL-6 at the transcriptional level. Recent reports show that glucocorticoids selectively inhibit IL-1 gene expression at the transcriptional l e~e l .~~'~~ The precise mechanism of IL-6 gene regulation by glucocorticoids remains to be clarified.
Glucocorticoids inhibited bone resorption induced by ILlj3 (OAF). Although it is still unclear whether IL-1 can act on osteoclast or not, osteoblasts but not osteoclasts have glucocorticoid receptor^.^' Thus it is likely that glucocorticoids have some effects on osteoblasts and indirectly inhibit functions of osteoclast. On the other hand, glucocorticoids upregulated the effect of PTH: glucocorticoids were reported to augment the expression of PTH receptors on osteoblasts!' Bone resorption induced by PTH and accelerated in the presence of glucocorticoids could be completely inhibited by calcitonin!' Calcitonin has direct effect on osteoclasts and inhibits bone resorption, but has no effect on myeloma cells: proliferation and M-protein secretion of myeloma cells were not affected by calcitonin, and calcitonin could not modulate the expression of IL-6 and IL-lj3 mRNA in myeloma cells.
In this context, glucocorticoids are useful chemotherapeutic agents that inhibit bone resorption in myelomas, particularly when calcitonin is used in combination with glucocorticoids; glucocorticoids suppressed not only the expression of IL-18 (OAF) mRNA in myeloma cells, but also bone resorption induced by IL-18. Furthermore, calcitonin completely inhibited PTH-induced bone resorption that was augmented by glucocorticoids.
Therefore we conclude that glucocorticoids are more effective chemotherapeutic agents in multiple myeloma than what we have always expected, and the regulatory mechanism of glucocorticoids on IL-6 gene expression could contribute to the understanding of transcriptional regulation of IL-6 gene activation.
